JCB logo
Accuri Cytometers
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 28 January 2002. doi:10.1083/jcb1563iti1
This Article
Right arrow Full Text (PDF, 317K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, W. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wells, W. A.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

© The Rockefeller University Press, 0021-9525/2002/2/411 $5.00
The Journal of Cell Biology, Volume 156, Number 3, February 4, 2002 411-411


In This Issue

With Aß, the danger lies within


Intracellular injection of Aß1–42 induces neuronal cell death and TUNEL staining (green).

The most obvious symptom is not always the most relevant. In Alzheimer's disease (AD), for example, post-mortem brain analyses show large extracellular amyloid plaques of fibrillar Aß protein. But the plaques arise late, whereas an intracellular version of the toxic protein fragment (Aß1–42, a fragment of the amyloid precursor protein) is seen earlier, coincident with the first cognitive defects. Now Zhang et al. (page 519) show that minute amounts of this intracellular Aß1–42 are toxic to primary neurons, even when injected directly into the cytoplasm.The final concentration of injected Aß1–42 is 1–100 pM, for a total of somewhere between 1,500 and 150,000 molecules per neuron. In contrast, the same neurons are not significantly affected by up to 10 µM extracellular 1–42, nor by intracellular Aß1–40, perhaps because the Aß1–40 cannot multimerize. Death requires transcription and translation, and the activities of p53, Bax, and caspase 6, probably in that order. The pathway from Aß1–42 to p53 remains a mystery. Zhang et al. are now looking at kinases that are known to regulate p53 activity.

What goes wrong first in AD is also not clear. If Aß1–42 exerts its activity in the cytoplasm it must first escape from the secretory pathway. Zhang et al. suggest this may happen by either reverse translocation from the ER or leakage from endosomes. As the details of these pathways are fleshed out, both the trafficking and apoptotic pathways may become excellent targets for AD drugs. {blacksquare}



William A. Wells

wellsw{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

Selective cytotoxicity of intracellular amyloid ß peptide1–42 through p53 and Bax in cultured primary human neurons
Yan Zhang, Richard McLaughlin, Cynthia Goodyer, and Andréa LeBlanc
J. Cell Biol. 2002 156: 519-529. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF, 317K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, W. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wells, W. A.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents